Last reviewed · How we verify
Famotidine 20 MG
Famotidine 20 MG is a Histamine-2 Receptor Antagonist [EPC] Small molecule drug developed by Chattogram General Hospital. It is currently FDA-approved. Also known as: Famotac 20mg, gaster.
At a glance
| Generic name | Famotidine 20 MG |
|---|---|
| Also known as | Famotac 20mg, gaster |
| Sponsor | Chattogram General Hospital |
| Drug class | Histamine-2 Receptor Antagonist [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor (PHASE2)
- An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases (PHASE1)
- Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) (PHASE2)
- The Seven Trial: Exploiting the Unfolded Protein Response (PHASE1)
- Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat (PHASE1)
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (PHASE1)
- Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia (PHASE4)
- Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Famotidine 20 MG CI brief — competitive landscape report
- Famotidine 20 MG updates RSS · CI watch RSS
- Chattogram General Hospital portfolio CI
Frequently asked questions about Famotidine 20 MG
What is Famotidine 20 MG?
Famotidine 20 MG is a Histamine-2 Receptor Antagonist [EPC] drug developed by Chattogram General Hospital.
Who makes Famotidine 20 MG?
Famotidine 20 MG is developed and marketed by Chattogram General Hospital (see full Chattogram General Hospital pipeline at /company/chattogram-general-hospital).
Is Famotidine 20 MG also known as anything else?
Famotidine 20 MG is also known as Famotac 20mg, gaster.
What drug class is Famotidine 20 MG in?
Famotidine 20 MG belongs to the Histamine-2 Receptor Antagonist [EPC] class. See all Histamine-2 Receptor Antagonist [EPC] drugs at /class/histamine-2-receptor-antagonist-epc.
What development phase is Famotidine 20 MG in?
Famotidine 20 MG is FDA-approved (marketed).
Related
- Drug class: All Histamine-2 Receptor Antagonist [EPC] drugs
- Manufacturer: Chattogram General Hospital — full pipeline
- Also known as: Famotac 20mg, gaster
- Compare: Famotidine 20 MG vs similar drugs
- Pricing: Famotidine 20 MG cost, discount & access